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Background: Patients with severe autosomal recessive congenital ich-
thyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in
their skin and serum, resembling the inflammatory profile of psoriatic pa-
tients. Secukinumab, an IL‐17A inhibitor, has shown clinical efficacy in pa-
tients with moderate‐to‐severe plaque psoriasis.
Aims: To test the clinical efficacy and safety of secukinumab in a paediatric
patient with ATP‐binding cassette subfamily A member 12 deficiency‐
related severe erythrodermic ARCI.
Materials & Methods: 6‐months therapeutic trial. During the first 4‐weeks
induction period, the patient received weekly subcutaneous injections of
150 mg secukinumab (five injections in total). During the following 20‐
weeks maintenance period, the patient was given a subcutaneous injec-
tion of 150 mg secukinumab every 4 weeks.
Result & Discussion: After the 6‐months therapy period, there was a 48%
reduction from the baseline Ichthyosis‐Area‐Severity‐Index (‐Erythema/‐
Scaling) score. The treatment was well tolerated. Moreover, cytokine
analysis revealed a reduction of keratinocyte‐derived proinflammatory
cytokines and an abrogation of Th17‐skewing during therapy.
Conclusion: Further studies are needed to evaluate the effects of the use of
IL‐17A inhibition in ARCI patients.
1 | INTRODUCTION
Autosomal recessive congenital ichthyoses (ARCI)
include a group of heterogeneous keratinisation disor-
ders. The clinical manifestations range from relatively
mild lamellar ichthyosis and erythrodermic ARCI to the
most severe, harlequin ichthyosis.1
In the granular layer keratinocytes, the ATP‐binding
cassette subfamily A member 12 (ABCA12) enables the
transport of lipids into the lamellar granules whose
content is released into the interstitial lipid domain
between the terminally differentiated keratinocytes.2
The intercellular lipid layers (ILLs) in the stratum cor-
neum are essential to maintain the epidermal skin
barrier function.3 Complete ABCA12 deficiency causes
harlequin ichthyosis, whereas variants with residual
activity lead to ARCI manifestations,4 due to defective
ILL formation, keratinocyte differentiation and skin
desquamation, causing epidermal skin barrier disrup-
tion and hyperkeratosis.3
Keratinocytes are the major target of the proin-
flammatory interleukin 17A (IL‐17A),5 which is pri-
marily produced by T helper cells type 17 (Th17)6
(Figure S1). IL‐17A has been recognised as a key
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cytokine that drives inflammatory pathways in the
pathogenesis of psoriasis.5 Secukinumab, an IL‐17A
inhibitor, has been approved for the treatment of pa-
tients with moderate to severe plaque psoriasis.7 In
patients with ichthyosis, a Th17/IL‐17 skewing in skin
and serum has been demonstrated, resembling the
expression profile of psoriatic patients.8,9 Hence, the
therapeutic approach for psoriasis may also be prom-
ising in patients with ichthyosis.9
Here we present, to our knowledge, the first paedi-
atric patient with ABCA12 deficiency‐related eryth-
rodermic ichthyosis who showed relevant improvement
under treatmentwith secukinumab. The patient's severe
skin condition with generalised erythema and scaling
required extensive and time‐consuming, yet insufficient
therapy. Given the patient's considerably impaired
quality of life, we performed an individual off‐label 6‐
months therapeutic trial with secukinumab. The treat-
ment was continued afterwards and is still maintained.
2 | MATERIALS AND METHODS
Written informed consent for both the off‐label treat-
ment and publication of the case, including the pictures,
was obtained from the patient family. All procedures
were performed in accordance with local institutional
review board requirements. Approval by the respon-
sible ethics committee was waived.
This individual off‐label 6‐months therapeutic trial
involved an 8‐year‐male patient with the clinical diag-
nosis of erythrodermic ARCI (see Case History in
Supporting Information Material). The skin biopsy
showed dermatitis with psoriasis‐like characteristics.
The symptomatic therapy with different emollients and
mild keratolytic was continued during the trial with no
change apart from frequency and duration of topical
skin care, which were adapted to need.
During the first 5‐weeks induction period, the pa-
tient (body weight 21 kg) received weekly subcutane-
ous injection of 150 mg secukinumab (Cosentyx®;
Novartis Pharma AG), followed by a 20‐weeks
maintenance period, with injections every 4 weeks,
according to the manufacturer's recommendations.
Visits to the clinic took place on Weeks 0 (baseline),
2, 4, 8, 11, 16, 20 and 26. The clinical efficacy of
secukinumab was assessed by standardised pictures of
the skin, as well as a battery of clinical scorings. The
safety of the drug was evaluated by general physical
examination and diary of adverse events, including
intercurrent illnesses, infections and other known side
effects of secukinumab. Safety laboratory analyses
were performed.
Measurement of cytokines in serum: Serum samples
were taken from the patient before and at 1, 3 and 6
months of therapy. For further information, see eMethods
in the Supporting Information Materials.
3 | RESULTS
The treatment was generally well tolerated with no
side effects or new symptoms during the whole 6‐
months treatment period. Safety laboratory analyses
showed no adverse findings.
Clinical follow‐up is summarised in Table 1.
Baseline scores of Investigator's Global Assessment
and Clinical Global Impression (‐Severity) (CGI‐S)
reflected the patient's severe condition (Table 1).
Under treatment, scaling and erythema declined.
Only 4 weeks after the start of therapy, there was a
38% reduction of the baseline Ichthyosis‐Area‐
Severity‐Index score (Table 1). At 8 weeks follow‐up
visit, the skin regained a rough, scaly and erythem-
atous appearance (Table 1), with recurrence of hy-
perkeratosis, but of a decreased area in all body
regions. At 11 and 16 weeks, the skin condition
showed again minimal improvement (CGI‐I 3), with
mild palmoplantar hyperkeratosis. Both erythema and
scaling decreased, while the facial area remained
erythematous (Figure 1). At 20 weeks follow‐up visit,
the skin remained slightly scaly, but altogether the
skin condition improved much (CGI‐I 2) and became
more stable.
Under secukinumab treatment, the required time for
the basic therapy was shortened by 20 min/day. Occa-
sionally and towards the end of the 6‐months therapy
period, daily bathing could be skipped and the extent of
topical treatment could be reduced. The maculopapular
rash was milder and observed only intermittently for a
What is already known about this topic?
� In patients with ichthyosis, a T helper 17/
interleukin 17 (IL‐17) skewing in skin and
serum has been demonstrated, resembling
the expression profile of psoriatic patients.
� IL‐17A inhibitor is an approved biologic
treatment for patients with moderate to se-
vere plaque psoriasis, not yet for patients
with ichthyosis.
What does this study add?
� Secukinumab was effective and well toler-
ated in the treatment of a paediatric patient
with ATP‐binding cassette subfamily A
member 12 deficiency‐related severe eryth-
rodermic ichthyosis.
� Clinical efficacy was accompanied by a
consistent shift in the cytokine profile in the
patient serum.
� The use of secukinumab in ichthyosis repre-
sents a promising therapeutic approach.
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few days. With the addition of an oral antihistaminic
treatment during the second month of secukinumab
treatment, the itching became tolerable. Moreover, the
regular ear cleanings had become more manageable, as
the ear canals were less moist and inflamed.
Results of the cytokine analysis in patient's sera are
shown in Figure 2. It revealed a milieu strongly
enriched in pro‐inflammatory Th1 cytokines IL‐1β,
tumour necrosis factor α (TNF‐α) and IL‐8 before
treatment. Moreover, a Th17 skewing was observed as
evidenced by the presence of the Th17 differentiating
cytokine IL‐23 and the Th17 cell‐derived cytokines
IL‐17A and IL‐22. IL‐36γ, a putative biomarker of
psoriasis, and IL‐38, an antagonist of IL‐36γ, were also
detectable in patient's serum at time point 0. During
treatment, we observed a significant reduction of IL‐22
and IL‐23 in patient's sera. In contrast, the levels of all
other tested cytokines remained high during the
administration of secukinumab. For further information,
see Case History in the Supporting Information Material.
4 | DISCUSSION
In children with congenital non‐syndromic ichthyosis,
secukinumab has not been used so far, and no clinical
trials have assessed its safety and efficacy in children in
general. Two paediatric case reports showed the
successful use of secukinumab in IL‐36 antagonist defi-
ciency with generalised skin eruptions and in psoriatic
arthritis.10,11 There is an ongoing randomised, double‐
blind phase II clinical trial (NCT03041038) on the effi-
cacy and safety of a 16‐weeks use of secukinumab in
adult patients with ichthyosis (https://clinicaltrials.gov/
ct2/show/NCT03041038, last accessed on 18 August
2020). Meanwhile, Hernandez‐Martin et al.12 have very
recently published their clinical experience with one in-
fant with a severe skin dermatitis, multiple allergies and
metabolic wasting‐like syndrome who showed clinical
improvement under secukinumab.
This individual trial shows the efficacy and safety of
secukinumab for the treatment of ABCA12 deficiency‐
related ichthyosis in a child. Secukinumab has been
reported to be fast and effective in the reduction of
psoriasis symptoms.7 During the induction period, this
prompt efficacy was observed in our patient; erythema
and scaling, showed striking improvement. With the
transition to monthly injections, the skin condition
improved again and stabilised after an initial transient
deterioration. Our patient had no increased or oppor-
tunistic infections nor any other occurrence suggestive
of an adverse drug reaction.
Patients with ichthyosis are reported to have a
higher concentration of IL‐17A.8,9 Accompanying this
individual therapeutic trial, we have performed a
cytokine profiling. Interestingly, the levels of the
proinflammatory Th1 cytokines IL‐1β and TNF‐α were
40‐ and 30‐fold increased, respectively, compared to
studies of patients with other dermatological condi-
tions, including paediatric ichthyosis13 and adult pso-
riasis.14 Moreover, these Th1 cytokine levels remained
high during treatment underscoring the prolonged
systemic Th1 inflammation in our patient. Moreover, a
Th17 skewing was observed as evidenced by the
presence of the Th17 differentiating cytokine IL‐23 and
the Th17 cell‐derived cytokines IL‐17A and IL‐22. IL‐
36γ, which has been described as a biomarker of pso-
riasis15 and IL‐38, an antagonist of IL‐36γ, were also
detectable in patient's serum at time point 0. Consis-
tently, recently published studies report high
expression of IL‐36γ in skin samples obtained from
ichthyosis16 and psoriasis patients.17 Moreover, treat-
ment with secukinumab resulted in reduced systemic
and local IL‐36γ expression accompanied by an upre-
gulation of IL‐38.17 Also, the study of Enjalbert et al.16
describes an opposing expression of IL‐36γ and its
antagonist IL‐37, whereby the former is expressed at
high and the later at low levels in patient's skin.
Interestingly, IL‐36γ and IL38 levels declined during
F I GUR E 1 Clinical follow up. Pictures taken at baseline visit (a),
and after 11 (b), 20 (c) and 26 (d) weeks of treatment, respectively,
show its clear and persistent efficacy with albeit varying residual
disease activity. The gastrostomy button on the left abdomen was
inserted for the treatment of underfeeding during early childhood
(with kind permission of the patient and his parents)
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secukinumab therapy in our patient indicating that the
agonist‐antagonist axis of IL‐36γ and IL‐38 seems not
to play a role here.
We detected increased levels of IL‐17A following
secukinumab therapy. We assume that these detected
higher levels of IL‐17A were due to complex formation
between IL‐17Aand secukinumab. Secukinumab‐IL‐17A
complexes are less efficiently cleared from the systemic
circulation resulting in accumulation of total IL17A
(secukinumab‐IL17A complexes plus free IL‐17A), which
reach a plateau at 6 months.18 Hence, while the IL‐17
enzyme‐linked immunosorbent assay is suitable to
F I GUR E 2 Serum cytokine profiles of the patient before and under anti‐IL‐17 antibody therapy. Quantification of serum cytokines, IL‐1β
(a), TNF‐α (b), IL‐8 (c), IL‐17A (d), IL‐22 (e), IL‐23 (f), IL‐36γ (g), and IL‐38 (h) using ELISA. Data shown are of patient's samples (shaded bars)
collected before (T0) and at 1, 3 and 6 months (T1, T1, T6) of anti‐IL‐17 antibody therapy. Controls are the mean from six age‐matched
control subjects with presumably normal cytokine profile (for details see eMethods in Supporting Information Materials). All data are shown
as mean ± SEM of replicates/data sets. ELISA, enzyme‐linked immunosorbent assay; IL, interleukin; nd, not detectable; TNF‐α, tumour
necrosis factor α. *p < 0.05 by unpaired nonparametric Kruskal–Wallis test with Dunnett's multiple group comparison
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determine total IL‐17A, it does not allow the discrimi-
nation between biological active (free IL‐17) and inac-
tive (complexed) IL‐17. Importantly, however, the
therapy seemed to decrease the Th17 milieu as evi-
denced by reduced serum IL‐23 and IL‐22 levels.
Moreover, we observed reduced levels of keratinocyte‐
derived proinflammatory cytokines, resulting in less
severe skin inflammation. While the IL‐17 antagonists
may thus reduce the skin Th17 inflammation, it does not
affect the production of Th1 cytokines, and it might not
improve the intrinsic epidermal barrier defects due to
the ABCA12 deficiency.19 IL‐profiling in skin biopsies of
the patient would have been advantageous but was not
performed because deemed too invasive in this context.
5 | CONCLUSIONS
In this individual trial, secukinumab was effective and
well tolerated in the treatment of a child with severe
erythrodermic ichthyosis. Clinical efficacy was accom-
panied by a consistent shift in the cytokine profile in
the patient serum.
To our knowledge, this is the first report of the use
of secukinumab in a paediatric patient with ABCA12
deficiency‐related severe erythrodermic ARCI. Further
studies including more patients and for longer duration
are needed to evaluate the use of this promising
therapeutic approach in congenital ichthyosis, in terms
of sustained efficacy and safety, especially in children
and patients with syndromic subtypes.
ACKNOWLEDGEMENTS
We thank the patient and his family for their great
compliance with the constraints of the follow‐up and
their critical review of the manuscript and permission
to publish these data.
CONFLICT OF INTEREST





1. Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C,
Bourrat E, et al. Revised nomenclature and classification of
inherited ichthyoses: results of the First Ichthyosis Consensus
Conference in Sorèze 2009. J Am Acad Dermatol.
2010;63(4):607–41.
2. Akiyama M. The roles of ABCA12 in epidermal lipid barrier
formation and keratinocyte differentiation. Biochim Biophys
Acta. 2014;1841(3):435–40.
3. Haller JF, Cavallaro P, Hernandez NJ, Dolat L, Soscia SJ, Welti R,
et al. Endogenous β‐glucocerebrosidase activity in Abca12‐/‐
epidermis elevates ceramide levels after topical lipidapplicationbut
does not restore barrier function. J Lipid Res. 2014;55(3):493–503.
4. Akiyama M. Corneocyte lipid envelope (CLE), the key structure
for skin barrier function and ichthyosis pathogenesis. J Der-
matol Sci. 2017;88(1):3–9.
5. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin
17A: toward a new understanding of psoriasis pathogenesis.
J Am Acad Dermatol. 2014;71(1):141–50.
6. Gaffen SL. Structure and signalling in the IL‐17 receptor family.
Nat Rev Immunol. 2009;9(8):556–67.
7. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM,
Papp K, et al. Secukinumab in plaque psoriasis—results of two
phase 3 trials. N Engl J Med. 2014;371(4):326–38.
8. Malik K, He H, Huynh TN, Tran G, Mueller K, Doytcheva K, et al.
Ichthyosis molecular fingerprinting shows profound TH17
skewing and a unique barrier genomic signature. J Allergy Clin
Immunol. 2019;143(2):604–18.
9. Paller AS. Profiling immune expression to consider repurpos-
ing therapeutics for the ichthyoses. J Invest Dermatol. 2019;
139(3):535‐40.
10. Köstner K, Prelog M, Almanzar G, Fesq H, Haas J‐P, Hügle B.
Successful use of secukinumab in a 4‐year‐old patient with
deficiency of interleukin‐36 antagonist. Rheumatology.
2018;57(5):936–8.
11. Wells LE, Evans T, Hilton R, Wine Lee L, Ruth N. Use of secu-
kinumab in a pediatric patient leads to significant improvement
in nail psoriasis and psoriatic arthritis. Pediatr Dermatol.
2019;36(3):384–5.
12. Hernández‐Martín A, Kennedy‐Batalla R, Cañedo E, Bernaldo‐
de‐Quirós E, Carazo‐Gallego B, Vera A, et al. Imbalance in
T‐helper 17 cells and targeted therapy in an infant with SAM‐
like syndrome. N Engl J Med. 2019;381(22):2176–8. https://doi.
org/10.1056/NEJMc1908531
13. Renner ED, Hartl D, Rylaarsdam S, Young ML, Monaco‐
Shawver L, Kleiner G, et al. Comèl‐Netherton syndrome
defined as primary immunodeficiency. J Allergy Clin Immunol.
2009;124:536–43.
14. Takahashi H, Tsuji H, Hashimoto Y, Ishida‐Yamamoto A, Iizuka
H. Serum cytokines and growth factor levels in Japanese pa-
tients with psoriasis. Clin Exp Dermatol. 2010;35:645–9.
15. D'Erme AM, Wilsmann‐Theis D, Wagenpfeil J, Hölzel M, Ferring‐
Schmitt S, Sternberg S, et al. IL‐36γ (IL‐1F9) Is a Biomarker for
Psoriasis Skin Lesions. J Invest Dermatol. 2015;135:1025–32.
16. Enjalbert F, Dewan P, Caley MP, Jones EM, Morse MA, Kelsell
DP, et al. 3D model of harlequin ichthyosis reveals inflamma-
tory therapeutic targets. J Clin Invest. 2020;130(9):4798–810.
17. Mercurio L, Morelli M, Scarponi C, Eisenmesser EZ Doti N
Pagnanelli, et al. IL‐38 has an anti‐inflammatory action in
psoriasis and its expression correlates with disease severity
and therapeutic response to anti‐IL‐17A treatment. Cell
Death Dis. 2018;9(11):1104. https://doi.org/10.1038/s41419‐
018‐1143‐3.
18. Bruin G, Loesche C, Nyirady J, Sander O. Population pharma-
cokinetic modeling of secukinumab in patients with moderate
to severe psoriasis. J Clin Pharmacol. 2017;57:876–85.
19. Cottle DL, Ursino GMA, Ip SCI, Jones LK, Ditommaso T,
Hacking DF, et al. Fetal inhibition of inflammation improves
disease phenotypes in harlequin ichthyosis. Hum Mol Genet.
2015;24(2):436–49.
SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of this
article.
How to cite this article: Yogarajah J, Gouveia C,
Iype J, et al. Efficacy and safety of secukinumab
for the treatment of severe ABCA12 deficiency‐
related ichthyosis in a child. Skin Health Dis.
2021;1:e25. https://doi.org/10.1002/ski2.25
6 of 6 - YOGARAJAH ET AL.
